Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) Shares Shorted: Short Interest Down 39.7% in September

Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 2,984 shares, a decline of 39.7% from the September 15th total of 4,949 shares. Based on an average daily volume of 2,478 shares, the short-interest ratio is currently 1.2 days.

Insider Activity

In related news, CEO Jodie Pope Morrison sold 3,221 shares of the company’s stock in a transaction dated Tuesday, October 6th. The stock was sold at an average price of $8.32, for a total value of $26,798.72. Following the completion of the sale, the chief executive officer directly owned 340,038 shares of the company’s stock, valued at $2,829,116.16. This represents a 0.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the completion of the sale, the insider directly owned 127,771 shares of the company’s stock, valued at approximately $2,115,887.76. This trade represents a 2.14% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 22,054 shares of company stock valued at $320,397.

Leverage Shares 2X Long FIX Daily ETF Stock Down 6.5%

Shares of BATS FIXX opened at $10.29 on Friday. Leverage Shares 2X Long FIX Daily ETF has a twelve month low of $9.14 and a twelve month high of $15.92.

Homology Medicines, Inc was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders.

Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases.